Focal Seizure
Neurology
2
Pipeline Programs
2
Companies
1
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Praxis Precision MedicinesMA - Boston
1 program1
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeksPhase 2/3
Precision BioSciencesDURHAM, NC
1 program1
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeksPhase 2/31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2024
2025
2026
Precision BioSciences20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
Clinical Trials (1)
Total enrollment: 230 patients across 1 trials
NCT06999902Precision BioSciences20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks
Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)
Start: Dec 2024Est. completion: Dec 2025230 patients
Phase 2/3Recruiting
Related Jobs in Neurology
Director, Distribution & Services
Xenon Pharmaceuticals
Remote
10h ago
Senior Medical Science Liaison (NYC Tri-State)
Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr
Director of Medical Affairs
CoMind
Miami, FL
10h ago
Director of Finance
CoMind
London, UK
10h ago
Electronics Engineering Manager
CoMind
London, UK
10h ago
Director of Information Technology
Zavation Medical Products
10h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 230 patients
2 companies competing in this space